

NCT03033745 Raw comparison:

Summary:
CHIA has 12 criteria while your personal folder has 16 criteria
Total found criteria: 12/12
Total not Found: 0/12
Total Extra: 4
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Male or female on stable dose of IgPro20           │ Male or female on stable dose of IgPro20           │
│ (Hizentra) therapy                                 │ (Hizentra) therapy                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Women of childbearing potential must be using and  │ Women of childbearing potential must be using and  │
│ agree to continue using medically approved         │ agree to continue using medically approved         │
│ contraception (which must be discussed with the    │ contraception (which must be discussed with the    │
│ study doctor) and must have a negative pregnancy   │ study doctor) and must have a negative pregnancy   │
│ test at screening                                  │ test at screening                                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects with PID eg with a diagnosis of common    │ Subjects with PID eg with a diagnosis of common    │
│ variable immunodeficiency or X-linked              │ variable immunodeficiency or X-linked              │
│ agammaglobulinemia as defined by the Pan American  │ agammaglobulinemia as defined by the Pan American  │
│ Group for Immune Deficiency and the European       │ Group for Immune Deficiency and the European       │
│ Society of Immune Deficiencies                     │ Society of Immune Deficiencies                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ With infusion parameters as specified below        │ With infusion parameters as specified below        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Experience with pump-assisted infusions of IgPro20 │ Experience with pump-assisted infusions of IgPro20 │
│ at the tolerated flow rate of 25 mL/h per          │ at the tolerated flow rate of 25 mL/h per          │
│ injection site for at least 1 month prior to Day 1 │ injection site for at least 1 month prior to Day 1 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Total weekly IgPro20 dose of = 50 mL (= 10 g)      │ Total weekly IgPro20 dose of ≥ 50 mL (≥ 10 g)      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Experience with pump-assisted infusions of IgPro20 │ Experience with pump-assisted infusions of IgPro20 │
│ at tolerated volumes of 25 mL/injection site for   │ at tolerated volumes of 25 mL/injection site for   │
│ at least 1 month prior to Day 1                    │ at least 1 month prior to Day 1                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Experience with frequent (2-7 times per week)      │ Experience with frequent (2-7 times per week)      │
│ infusions of IgPro20 at the tolerated flow rate of │ infusions of IgPro20 at the tolerated flow rate of │
│ approximately 0 5 mL/min (equivalent of 25-30      │ approximately 0 5 mL/min (equivalent of 25-30      │
│ mL/h) per injection site for at least 1 month      │ mL/h) per injection site for at least 1 month      │
│ prior to Day 1 The dose (volume) per injection     │ prior to Day 1 The dose (volume) per injection     │
│ site should not exceed 25 mL                       │ site should not exceed 25 mL                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Ongoing serious bacterial infections at the time   │ Ongoing serious bacterial infections at the time   │
│ of screening                                       │ of screening                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Other significant medical conditions that could    │ Other significant medical conditions that could    │
│ increase the risk to the subject                   │ increase the risk to the subject                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Females who are pregnant breast feeding or         │ Females who are pregnant breast feeding or         │
│ planning a pregnancy during the course study       │ planning a pregnancy during the course study       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Participation in a study with an Investigational   │ Participation in a study with an Investigational   │
│ Medicinal Product (IMP) other than IgPro20 within  │ Medicinal Product (IMP) other than IgPro20 within  │
│ three months prior to enrollment                   │ three months prior to enrollment                   │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒══════════════════════════════════════════════╕
│ Extra Personal Criteria                      │
╞══════════════════════════════════════════════╡
│ Manual Push Flow Rate Cohort subjects only   │
├──────────────────────────────────────────────┤
│ Pump-Assisted Flow Rate Cohort subjects only │
├──────────────────────────────────────────────┤
│ Must have minimum age of 2 Years             │
├──────────────────────────────────────────────┤
│ Pump-Assisted Volume Cohort subjects only    │
╘══════════════════════════════════════════════╛